GlassScriptPhysician profile
Robert S Callahan
NPI 1962491779
$6,899.73
in general payments reported to CMS, 2019-2025
50 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $688 · 2021: $666 · 2022: $722 · 2023: $1,096 · 2024: $1,453 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,690.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.77 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $889.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $639.77 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $467.33 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $466.59 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Gilead Sciences, INC. | $417.35 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $352.81 | 2019-2025 | Vaxneuvance, Gardasil 9, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.15 | 2019-2025 | Jardiance |
| Lundbeck LLC | $251.40 | 2022-2024 | Vyepti |
| Pfizer INC. | $196.15 | 2019-2025 | |
| Astellas Pharma US INC | $173.08 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $149.27 | 2020-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $126.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Jazz Pharmaceuticals INC. | $90.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $87.98 | 2019-2025 | Spravato, Xarelto |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.